Increased Immunogenicity of Inactivated Influenza Virus Vaccine Containing Purified Surface Antigen Compared with Whole Virus in Elderly Women

Overview

Journal Clin Diagn Lab Immunol

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 1994 Jan 1

PMID 7496915

Citations 4

Authors

D C Powers

Affiliations

Soon will be listed here.

Abstract

Thirty-eight elderly female subjects (aged 80 +/- 7 years, mean +/- standard deviation) were randomized to immunization with trivalent inactivated influenza virus vaccine containing either purified surface antigen (n = 18) or whole virus (n = 20) components from A/Texas/36/91 (H1N1), A/Beijing/353/89 (H3N2), and B/Panama/45/90 strains. Humoral and cellular immune responses were assessed by measuring serum hemagglutination inhibition antibodies and cytotoxic T lymphocyte (CTL) activity at 0 and 3 weeks postvaccination. Serological responses to both of the type A vaccine strains following immunization with surface antigen vaccine (SAV) were significantly more frequent and greater in magnitude than those induced by whole-virus vaccine. Antibody responses to the B/Panama component were modest and did not differ significantly between the two vaccines. Persons given SAV, but not those given whole-virus vaccine, had a small but significant increase in mean percent specific lysis of influenza A (H1N1) virus-infected autologous targets by peripheral blood mononuclear cells which were stimulated in vitro with influenza A (H1N1) virus. The H1N1-stimulated cytotoxic effectors induced by SAV were CD8+ and were not cross-reactive against H3N2-infected targets. Influenza B virus-specific CTL responses were not observed with either vaccine. These results suggest that currently available subunit influenza virus vaccines may offer an advantage over inactivated whole-virus preparations for inducing humoral and cellular immune responses in the elderly, although the CTL response may be too limited to be of physiological significance.

Citing Articles

Quantitative review of antibody response to inactivated seasonal influenza vaccines.

Seidman J, Richard S, Viboud C, Miller M Influenza Other Respir Viruses. 2011; 6(1):52-62.

PMID: 21668661 PMC: 3175249. DOI: 10.1111/j.1750-2659.2011.00268.x.

Comparison of Serology and Reactogenicity between Influenza Subunit Vaccines and Whole Virus or Split Vaccines: A Review and Meta-Analysis of the Literature.

Beyer W, Palache A, Osterhaus A Clin Drug Investig. 2008; 15(1):1-12.

PMID: 18370460 DOI: 10.2165/00044011-199815010-00001.

Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant.

Mbawuike I, Zang Y, Couch R Vaccine. 2007; 25(17):3263-9.

PMID: 17280748 PMC: 2017113. DOI: 10.1016/j.vaccine.2007.01.073.

Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.

GLATHE H, Lange W Drugs Aging. 1995; 6(5):368-87.

PMID: 7647426 DOI: 10.2165/00002512-199506050-00004.

References

Powers D . Immunological principles and emerging strategies of vaccination for the elderly. J Am Geriatr Soc. 1992; 40(1):81-94. DOI: 10.1111/j.1532-5415.1992.tb01835.x. View

McElhaney J, Meneilly G, Beattie B, Helgason C, Lee S, Devine R . The effect of influenza vaccination on IL2 production in healthy elderly: implications for current vaccination practices. J Gerontol. 1992; 47(1):M3-8. DOI: 10.1093/geronj/47.1.m3. View

Powers D . Influenza A virus-specific cytotoxic T lymphocyte activity declines with advancing age. J Am Geriatr Soc. 1993; 41(1):1-5. DOI: 10.1111/j.1532-5415.1993.tb05938.x. View

Palache A, Beyer W, Sprenger M, Masurel N, de Jonge S, Vardy A . Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine. 1993; 11(1):3-9. DOI: 10.1016/0264-410x(93)90333-s. View

Powers D, Belshe R . Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J Infect Dis. 1993; 167(3):584-92. DOI: 10.1093/infdis/167.3.584. View

PARKMAN P, HOPPS H, Rastogi S, MEYER Jr H . Summary of clinical trials of influenza virus vaccines in adults. J Infect Dis. 1977; 136 Suppl:S722-30. DOI: 10.1093/infdis/136.supplement_3.s722. View

POTTER C, Oxford J . Determinants of immunity to influenza infection in man. Br Med Bull. 1979; 35(1):69-75. DOI: 10.1093/oxfordjournals.bmb.a071545. View

Frank A, Webster R, Glezen W, CATE T . Immunogenicity of influenza A/USSR (H1N1) subunit vaccine in unprimed young adults. J Med Virol. 1981; 7(2):135-42. DOI: 10.1002/jmv.1890070207. View

McMichael A, Gotch F, Cullen P, Askonas B, Webster R . The human cytotoxic T cell response to influenza A vaccination. Clin Exp Immunol. 1981; 43(2):276-84. PMC: 1537292. View

10.

Ennis F, Meager A . Immune interferon produced to high levels by antigenic stimulation of human lymphocytes with influenza virus. J Exp Med. 1981; 154(5):1279-89. PMC: 2186530. DOI: 10.1084/jem.154.5.1279. View

11.

Ennis F, Rook A, Qi Y, Schild G, Riley D, Pratt R . HLA restricted virus-specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines. Lancet. 1981; 2(8252):887-91. DOI: 10.1016/s0140-6736(81)91389-1. View

12.

Brandriss M, Betts R, Mathur U, DOUGLAS Jr R . Responses of elderly subjects to monovalent A/USSR/77 (H1N1) and Trivalent A/USSR/77 (H1N1)-A/TEXAS/77 (H3N2)-B/Hong Kong/72 vaccines. Am Rev Respir Dis. 1981; 124(6):681-4. DOI: 10.1164/arrd.1981.124.6.681. View

13.

CATE T, Couch R, Parker D, Baxter B . Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines - 1978. Rev Infect Dis. 1983; 5(4):737-47. DOI: 10.1093/clinids/5.4.737. View

14.

Quinnan G, Schooley R, Dolin R, Ennis F, Gross P, Gwaltney J . Serologic responses and systemic reactions in adults after vaccination with monovalent A/USSR/77 and trivalent A/USSR/77, A/Texas/77, B/Hong Kong/72 influenza vaccines. Rev Infect Dis. 1983; 5(4):748-57. DOI: 10.1093/clinids/5.4.748. View

15.

Gross P, Quinnan Jr G, Weksler M, Gaerlan P, DENNING C . Immunization of elderly people with high doses of influenza vaccine. J Am Geriatr Soc. 1988; 36(3):209-12. DOI: 10.1111/j.1532-5415.1988.tb01802.x. View

16.

Peters N, MEIKLEJOHN G, Jahnigen D . Antibody response of an elderly population to a supplemental dose of influenza B vaccine. J Am Geriatr Soc. 1988; 36(7):593-9. DOI: 10.1111/j.1532-5415.1988.tb06152.x. View

17.

McElhaney J, Beattie B, Devine R, Grynoch R, Toth E, Bleackley R . Age-related decline in interleukin 2 production in response to influenza vaccine. J Am Geriatr Soc. 1990; 38(6):652-8. DOI: 10.1111/j.1532-5415.1990.tb01424.x. View

18.

Gorse G, Belshe R . Enhancement of anti-influenza A virus cytotoxicity following influenza A virus vaccination in older, chronically ill adults. J Clin Microbiol. 1990; 28(11):2539-50. PMC: 268221. DOI: 10.1128/jcm.28.11.2539-2550.1990. View

19.

Barry D, Mayner R, Staton E, Dunlap R, Rastogi S, Hannah J . Comparative trial of influenza vaccines. I. Immunogenicity of whole virus and split product vaccines in man. Am J Epidemiol. 1976; 104(1):34-46. DOI: 10.1093/oxfordjournals.aje.a112272. View

20.

Zei T, Neri M, Iorio A . Immunogenicity of trivalent subunit and split influenza vaccines (1989-90 winter season) in volunteers of different groups of age. Vaccine. 1991; 9(9):613-7. DOI: 10.1016/0264-410x(91)90184-8. View